Allarity Therapeutics, Inc.

For the period ended Dec 31, 2025. Filed Mar 30, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 30, 2026

ALLR$0.94-2.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

As of December 31, 2025 and 2024

(in thousands, except for share and per share data)

	December 31,	December 31,
	2025	2024
ASSETS
Current assets:
Cash	$14,687	$19,533
Receivables from ATM sales	—	1,416
Other current assets	265	115
Prepaid expenses	2,110	507
Tax credit receivable	866	770
Total current assets	17,928	22,341
Non-current assets:
Property, plant and equipment, net	330	309
Total assets	$18,258	$22,650
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$4,282	$4,182
Accrued expenses and other current liabilities	2,667	5,232
Warrant derivative liability	—	1
Income taxes payable	81	74
Convertible promissory note and accrued interest	1,400	1,350
Total current liabilities	8,430	10,839
Total liabilities	8,430	10,839
Commitments and contingencies (Note 14)
Stockholders’ equity
Common stock, $0.0001 par value (250,000,000 shares authorized); 19,030,619 and 7,302,797 shares issued and 16,080,980 and 7,302,797 outstanding at December 31, 2025, and December 31, 2024, respectively	3	1
Additional paid-in capital	144,233	131,130
Accumulated other comprehensive loss	(1,021)	(354)
Accumulated deficit	(130,197)	(118,966)
Treasury stock, at cost; 2,949,639 shares	(3,190)	—
Total stockholders’ equity	9,828	11,811
Total liabilities and stockholders’ equity	$18,258	$22,650

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.